/ PRODUCT FACT SHEET AND ORDERING INFORMATION

RYANODEX® (dantrolene sodium) for injectable suspension

RYANODEX® Specifications[1]

NDC	42367-540-32 (One vial)
Storage and Handling	• No refrigeration needed: stored unreconstituted product at controlled room temperature (68°F to 77°F or 20°C to 25°C) • 33-month shelf life from date of manufacture[2]
Reconstitution	RYANODEX® must be reconstituted prior to administration: • Add 5 mL of sterile water for injection (without a bacteriostatic agent) • Shake the vial to ensure an orange-colored uniform suspension – Should take approximately 10 seconds[2] • Visually inspect the vial for particulate matter and discoloration prior to administration • Must use the contents of the vial within 6 hours after reconstitution – Store reconstituted suspensions at controlled room temperature (68°F to 77°F or 20°C to 25°C)
Packaging Specifications	• Individual carton size: 38.1 mm x 38.1 mm x 76.2 mm • One vial per carton

Wholesale Information		
Distributor	**Item Number**	**Customer Service**
AmerisourceBergen (ABC)	10144143	844.222.2273
Cardinal Health (CAH)	5010343	800.926.3161
Cesar Castillo	1000022670	787.641.5082
Henry Schein Medical	122 – 8846	800.772.4346
McKesson Medical-Surgical	944053	855.571.2100
McKesson Specialty Health (McK)	3227584	855.625.4677
Medical Purchasing Solutions	RYAN250	888.894.2487
Morris & Dickson (M&D)	662411	800.388.3833

For additional information about RYANODEX®, contact your Key Account Manager, or visit **RYANODEX.COM**

See full Important Safety Information on the back, and accompanying full Prescribing Information for RYANODEX®

RYANODEX®
(dantrolene sodium)
for injectable suspension
250 mg per vial

INDICATION

RYANODEX® (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.

IMPORTANT SAFETY INFORMATION

RYANODEX® is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia (MH), including discontinuing use of MH-triggering anesthetic agents, managing the metabolic acidosis, instituting cooling when necessary, and administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX® is insufficient to maintain diuresis).

RYANODEX® is associated with skeletal muscle weakness such as loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of RYANODEX® into the surrounding tissue due to the high pH of the reconstituted RYANODEX® suspension and potential for tissue necrosis.

See accompanying full Prescribing Information for RYANODEX®

EAGLE® PHARMACEUTICALS

References

1. RYANODEX® [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2020.
2. Data on file. Eagle Pharmaceuticals, Inc.